Tildrakizumab Medicine 03 June 2025 Extended indication Tildrakizumab monotherapy for treatment of active psoriatic arthritis in adults and elderly who have prior exposure to anti-tumor necrosis factor agent. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Tildrakizumab Domain Chronic immune diseases Reason of inclusion New medicine (specialité) Main indication Skin diseases Extended indication Tildrakizumab monotherapy for treatment of active psoriatic arthritis in adults and elderly who have prior exposure to anti-tumor necrosis factor agent. Current proprietary name Already available biosimilars / generics Proprietary name Ilumetri Manufacturer Almirall Portfolio holder Almirall Mechanism of action Interleukin inhibitor Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date 2026 Expected Registration 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Fabrikant verwacht indiening in eerste kwartaal van 2026. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT03552276 Additional remarks De aanbevolen dosis is 100 mg via subcutane injectie op week 0 en 4 en elke 12 weken daarna. Naar het oordeel van de arts kan bij patiënten met een hoge ziektelast of bij patiënten met een lichaamsgewicht van meer dan 90 kg een dosis van 200 mg een grotere werkzaamheid bieden. Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 17,575.00 - 35,150.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks De prijs voor 100 mg Ilumetri is €3.192,82 (incl. BTW). Er zijn zes injecties van 100 mg nodig in het eerste jaar. Dit is €17.575,16 (excl. BTW). Er kan ook gekozen worden voor een dubbele dosis, dit kost dan €35.150,31 (excl. BTW). Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks